학술논문

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Document Type
article
Author
Bastard, PaulGervais, AdrianLe Voyer, TomRosain, JérémiePhilippot, QuentinManry, JérémyMichailidis, EleftheriosHoffmann, Hans-HeinrichEto, ShoheiGarcia-Prat, MarinaBizien, LucyParra-Martínez, AlbaYang, RuiHaljasmägi, LiisMigaud, MélanieSärekannu, KaritaMaslovskaja, Juliade Prost, NicolasTandjaoui-Lambiotte, YacineLuyt, Charles-EdouardAmador-Borrero, BlancaGaudet, AlexandrePoissy, JulienMorel, PascalRichard, PascaleCognasse, FabriceTroya, JesusTrouillet-Assant, SophieBelot, AlexandreSaker, KahinaGarçon, PierreRivière, Jacques GLagier, Jean-ChristopheGentile, StéphanieRosen, Lindsey BShaw, ElanaMorio, TomohiroTanaka, JunkoDalmau, DavidTharaux, Pierre-LouisSene, DamienStepanian, AlainMegarbane, BrunoTriantafyllia, VasilikiFekkar, ArnaudHeath, James RFranco, José LuisAnaya, Juan-ManuelSolé-Violán, JordiImberti, LuisaBiondi, AndreaBonfanti, PaoloCastagnoli, RiccardoDelmonte, Ottavia MZhang, YuSnow, Andrew LHolland, Steven MBiggs, CatherineMoncada-Vélez, MarcelaArias, Andrés AugustoLorenzo, LazaroBoucherit, SorayaCoulibaly, BoubacarAnglicheau, DanyPlanas, Anna MHaerynck, FilomeenDuvlis, SotirijaNussbaum, Robert LOzcelik, TayfunKeles, SevgiBousfiha, Ahmed ABakkouri, Jalila ElRamirez-Santana, CarolinaPaul, StéphanePan-Hammarström, QiangHammarström, LennartDupont, AnnabelleKurolap, AlinaMetz, Christine NAiuti, AlessandroCasari, GiorgioLampasona, VitoCiceri, FabioBarreiros, Lucila ADominguez-Garrido, ElenaVidigal, MateusZatz, Mayanavan de Beek, DiederikSahanic, SabinaTancevski, IvanStepanovskyy, YuriiBoyarchuk, OksanaNukui, YokoTsumura, MiyukiVidaur, LoretoTangye, Stuart GBurrel, SoniaDuffy, DarraghQuintana-Murci, LluisKlocperk, Adam
Source
Science Immunology. 6(62)
Subject
Pneumonia
Lung
Infectious Diseases
Emerging Infectious Diseases
Vaccine Related
Clinical Research
Pneumonia & Influenza
Prevention
Infection
Good Health and Well Being
Adolescent
Adult
Aged
Aged
80 and over
Antibodies
Neutralizing
Autoantibodies
COVID-19
Case-Control Studies
Child
Child
Preschool
Critical Illness
Humans
Immunoglobulin G
Infant
Infant
Newborn
Interferon Type I
Interferon-alpha
Middle Aged
Young Adult
HGID Lab
COVID Clinicians
COVID-STORM Clinicians
NIAID Immune Response to COVID Group
NH-COVAIR Study Group
Danish CHGE
Danish Blood Donor Study
St. James's Hospital
SARS CoV2 Interest group
French COVID Cohort Study Group
Imagine COVID-Group
Milieu Intérieur Consortium
CoV-Contact Cohort
Amsterdam UMC Covid-19
Biobank Investigators
COVID Human Genetic Effort
CONSTANCES cohort
3C-Dijon Study
Cerba Health-Care
Etablissement du Sang study group
Language
Abstract
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals 80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases.